Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

by NASDAQ Market News December 31, 2020

NASDAQ Market News
Click here to email author

Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

Medicenna Establishes At-the-Market Sales Facility

Ads